Ozempic face and cosmetic surgery: what the data actually shows

What did @cnn actually say?

CNN's Harry Enten made several numerical claims in rapid succession: one in eight U.S. adults have used a GLP-1 drug, 40% of those used it for weight loss, facelifts rose 8% from 2022 to 2023, hyaluronic acid fillers jumped 100% from 2017 to 2023, one in five GLP-1 users have had cosmetic surgery, two in five are considering it, and liposuction grew 1% last year rather than declining. He attributed the cosmetic surge partly to what he called the "hallowed-out face" phenomenon, citing dermatologist Dr. Paul Jared Frank's analogy about "refilling a deflated balloon." The segment presents these statistics as a connected causal story: GLP-1 drugs cause facial volume loss, which drives cosmetic procedures upward. That's a bigger leap than the numbers alone can support.

Does the science back this up?

Partly, but the causal framing is doing a lot of heavy lifting here. The GLP-1 adoption figures are plausible. A 2024 KFF Health Tracking Poll found roughly 12% of U.S. adults reported ever using a GLP-1 medication, aligning with the one-in-eight figure. The weight-loss usage breakdown also tracks with survey data. The cosmetic surgery statistics appear to originate from the American Society of Plastic Surgeons (ASPS) 2023 procedural statistics and a separate 2023 survey on GLP-1 users and cosmetic intent. However, the ASPS data does not directly attribute facelift or filler increases to GLP-1 usage. Correlation between two rising trends is not causation. Facial volume loss from rapid weight loss has been documented clinically, but peer-reviewed literature specifically isolating "Ozempic face" as a distinct, GLP-1-specific phenomenon remains limited. Rohrich et al. (2023, Plastic and Reconstructive Surgery) discussed weight-loss-related facial changes but noted the evidence base is still emerging.

What did they get wrong (or right)?

Credit where it's due: the adoption statistics are reasonably sourced and the general direction of the cosmetic surgery trend is supported by ASPS annual data. Enten is also right that liposuction hasn't cratered, which surprises a lot of people who assume GLP-1 drugs made it obsolete.

What's shakier: the 100% increase in hyaluronic acid fillers from 2017 to 2023 is presented without controlling for baseline trends. Filler use was already climbing steeply before semaglutide became a household name. Attributing that six-year doubling to Ozempic face is misleading framing. The ASPS data shows filler growth predates widespread GLP-1 adoption by years.

The one-in-five GLP-1 users having cosmetic surgery statistic also needs context. That figure likely comes from a self-reported survey, not a clinical dataset, and GLP-1 users skew toward demographics already more likely to pursue elective cosmetic procedures, higher income, greater healthcare access. Without controlling for that, you're not measuring a GLP-1 effect, you're measuring a selection effect.

What should you actually know?

Rapid weight loss, regardless of method, can cause facial volume loss. This is not new or unique to GLP-1 drugs. The speed of weight loss with semaglutide and tirzepatide may accelerate this effect compared to slower dietary changes, but that's a hypothesis still being studied, not settled science.

If you're using a GLP-1 medication and noticing facial changes, that's worth discussing with a physician, not a TikTok comment section. Hyaluronic acid fillers are a legitimate clinical option for volume restoration, but the decision involves individual anatomy, rate of weight change, and whether your weight has stabilized. Rushing to fill a face that's still losing volume can produce poor aesthetic results.

The broader data point worth taking seriously: GLP-1 drugs are reshaping multiple medical markets at once, including surgical and aesthetic medicine. That part of the story is real even if the specific causal arrows Enten draws are fuzzier than a cable news segment allows for.